Vital Statistics
| Class |
Ticker |
CUSIP |
Fund Number |
| Investor |
BIPIX |
743185-480 |
043 |
| Service |
BIPSX |
743185-472 |
073 |
Inception Date for all share classes is
6/19/2000
NAV
as of
1/5/2009
| Class |
NAV |
% Change |
$ Change |
| Investor |
$51.49 |
-0.46% |
-$0.24 |
| Service |
$47.41 |
-0.48% |
-$0.23 |
At a GlanceThe Biotechnology UltraSector ProFund provides leveraged exposure to the Dow Jones U.S. Biotechnology Index.
ObjectiveSeeks daily investment results, before fees and expenses, that correspond to 150%, of the daily performance of the Dow Jones U.S. Biotechnology Index.
There is no guarantee that any ProFund will achieve its investment objective. Investment return and principal value will vary and shares may be worth more or less at redemption than at original purchase. See the prospectus for more information.
This ProFund routinely employs leveraged investment techniques that magnify gains and losses and result in greater volatility in value.
This ProFund invests in a single industry. Its shares do not represent a complete investment program. As non-diversified and single industry fund, the value of its shares may fluctuate more than shares invested in a broader range of industries and companies.
|
Dow Jones U.S. Biotechnology Index
The Dow Jones U.S Biotechnology Index measures the performance of the biotechnology industry of the U.S. equity market. Component companies include those engaged in genetic research, and/or the marketing and development of recombinant DNA products. Makers of artificial blood and contract biotechnology researchers are also included in the Index. It is not possible to invest directly in an index.
Index (as of
9/30/2008)
|
|
Top 10 Index Companies
| Name |
Weight |
| Amgen Inc. |
23.37% |
| Gilead Sciences Inc. |
15.63% |
| Genentech Inc. |
15.32% |
| Celgene Corp. |
10.73% |
| Genzyme Corp. |
8.05% |
| Biogen Idec Inc. |
5.50% |
| Vertex Pharmaceuticals Inc. |
1.74% |
| Illumina Inc. |
1.73% |
| ImClone Systems Inc. |
1.43% |
| Charles River Laboratories International Inc. |
1.41% |
Total Index Companies
36
Average Index Market Capitalization
7.45 billion
|
|
Fund Statistics
| Limits On Exchanges |
None |
| Minimum Investment |
Individual Investor |
$15,000 |
|
Financial Professionals |
$5,000 |
|
All data, unless otherwise noted, is as of 9/30/2008 and for Investor Class Shares only and is subject to change.
07-00291
Investing in ProFunds involves certain risks, including in all or some cases, leverage, liquidity, concentration, non-diversification, foreign investment, foreign currency, high yield, interest rate, credit, market, correlation, aggressive investment technique and repurchase agreement risks. Moreover, there is no guarantee that any ProFund will achieve its investment objective. These risks can increase volatility and decrease performance. All ProFunds permit active investment strategies which can decrease performance and increase expenses.
|
|